Medical Article

August has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, Humana, Merck and Mayo Clinic named new executives. There were also layoffs at organizations including MaineHealth, Cellares and Sharp HealthCare. The post Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs appeared first on MedCity News.

In this episode, we’re joined by Amanda Shafton, practicing CNM and national director of midwifery at Ob Hospitalist Group. We discuss the benefits of physician/midwifery collaboration and how midwives can improve maternal health outcomes. The post MedCity FemFwd: How Midwives Can Support the Maternal Health Crisis appeared first on MedCity News.

Health tech companies made several major funding announcements in August. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in August appeared first on MedCity News.

Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options. Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company’s top overall product faces patent expirations. The post First-in-Class Takeda, Protagonist Drug Lands FDA Approval in Rare…

If AI is not one of the CEO’s top two or three priorities, the organization will produce pilots and slide decks while better-mobilized peers pull ahead and the institution’s ability to fulfill its mission erodes The post AI Won’t Transform Health Systems, CEOs Will — 6 Principles to Drive the Transformation appeared first on MedCity…

A new report found that while more than 90% of health systems have deployed third-party AI tools, less than half have the infrastructure to properly test and validate them before they become embedded in patient care. The post Hospitals Are All In on AI, but Testing and Oversight Haven’t Caught Up appeared first on MedCity…

Biohaven is outlicensing to SK Biopharmaceuticals global rights to opakalim, a Kv7-targeting small molecule in pivotal clinical testing for epilepsy. Biohaven gets non-dilutive financing for its pipeline while SK Bio gains another asset to potentially commercialize in the U.S. The post SK Bio Broadens U.S. Prospects, Licensing Late-Stage Epilepsy Drug From Biohaven appeared first on…

When the healthcare system defaults to uncertainty, people delay care because it feels safer for their wallets. In some cases, people wait too long, leaving an ER visit as the path of least resistance.  The post The Missing Piece in Lowering the Cost of Care: Predictability appeared first on MedCity News.